title: Efficacy of Subgingivally Delivered Satranidazole in the Treatment of Type 2 Diabetes Subjects with Chronic Periodontitis: A Randomized Controlled Clinical Trial.
abstract: BACKGROUND
  The present clinical trial was designed to investigate the effectiveness of subgingivally delivered satranidazole (SZ) gel as an adjunct to scaling and root planing (SRP) in the treatment of chronic periodontitis.
  
  
  METHODS
  Sixty-four subjects with probing depth (PD) ≥ 5 mm and who were diagnosed with type 2 diabetes were selected. Thirty-two subjects each were randomly assigned to SRP + placebo (Group 1) and SRP + SZ (Group 2). The clinical outcomes evaluated were plaque index (PI), gingival index (GI), clinical attachment level (CAL) and PD at baseline, 1 month, 3-months and 6 months.
  
  
  RESULTS
  At 6 months, Group 2 had greater mean reduction (4.73 mm) in PD as compared to Group 1 (2.09 mm; p < 0.05) and also a greater mean CAL gain (3.92 mm versus 1.64 mm; p < 0.05).
  
  
  CONCLUSIONS
  The use of 3% SZ gel, when used as an adjunct to non-surgical periodontal therapy in subjects with periodontitis, achieves significantly better clinical results than initial periodontal treatment alone.
authors.forename: N
authors.initials: N
authors.lastname: Priyanka
authors.forename: Nitish
authors.initials: N
authors.lastname: Kalra
authors.forename: Shahab
authors.initials: S
authors.lastname: Saquib
authors.forename: Shahabe
authors.initials: S
authors.lastname: Saquib
authors.forename: Nikhil
authors.initials: N
authors.lastname: Malgaonkar
authors.forename: Malgaonkar
authors.initials: M
authors.lastname: Nikhil
authors.forename: Bassel
authors.initials: B
authors.lastname: Tarakji
authors.forename: Jadhav
authors.initials: J
authors.lastname: Varsha
authors.forename: Davangere
authors.initials: D
authors.lastname: Umashree
authors.forename: A R
authors.initials: AR
authors.lastname: Pradeep
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000032:analysis; D055113:Chronic Periodontitis / Q000188:drug therapy*; D003131:Combined Modality Therapy; D003774:Dental Plaque Index; D012534:Dental Scaling / Q000379:methods; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D005782:Gels; D005883:Gingival Crevicular Fluid / Q000737:chemistry; D006801:Humans; D008297:Male; D008875:Middle Aged; D009593:Nitroimidazoles / Q000008:administration & dosage* / Q000032:analysis; D017622:Periodontal Attachment Loss / Q000188:drug therapy; D010512:Periodontal Index; D010514:Periodontal Pocket / Q000188:drug therapy; D010919:Placebos; D016745:Root Planing / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D005782:Gels; D009593:Nitroimidazoles; D010919:Placebos; C034473:satranidazole